The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.

A bioreactor has a cover, a container body, a sealing portion, a driving portion and a liquid guide portion. A ventilation structure and a bacteria-retaining sealing breathable structure provided in the cover, a cleaning liquid inlet portion penetrates the bottom of the driving portion, and a liquid inlet portion and a liquid outlet portion of the liquid guide portion are arranged penetrating a sidewall of the container body. The driving portion drives, by means of elastic deformation, a liquid to be replaced or a cleaning liquid to move up and down, such that the liquid to be replaced can enter the container body only through a gas-liquid channel, so as to subsequently prevent damage to hepatic cells due to a carrier bearing a shearing force, and enable the liquid to be replaced to gain full contact with the carrier. Further provided is a bioreaction system.

A bioartificial liver (BAL) based on human induced pluripotent stem cells (iPSCs)-derived hepatocyte-like cells (HLCs) and a multilayer porous bioreactor is provided. The plasma separation/retransfusion loop part includes a blood input pipe, an exhaust pipe spring clamp, a blood input peristaltic pump, a heparin pump, a plasma separation column, a first pressure monitor, and a heater. The cell reactor/plasma component exchange double-loop part includes a plasma input peristaltic pump, and a semipermeable membrane exchange column, a plasma exchange peristaltic pump, a red blood cell (RBC) pool, a membrane lung, a multilayer porous bioreactor, a second pressure monitor, and a third pressure monitor arranged in a 37° C. dedicated incubator. An outlet of the third pressure monitor and a blood cell outlet are connected to an inlet of the first pressure monitor, and then connected to the heater and a blood output pipe in sequence.

A blood treatment method includes the steps of inducing flow of a patient's blood through an extracorporeal device inlet and outlet in fluid connection to the circulatory system of the patient. Metastatic DNA contained within patient blood can be rendered non-oncogenic by passing patient blood over a biochemical reactor surface having attached or immobilized DNase 1 enzyme, with the biochemical reactor being contained within the extracorporeal device. The treatment method is performed without adding any chemicals to the blood of the patient.

The present invention provides methods and devices for augmenting impaired glycocalyx barrier function in a subject in need thereof by contacting a sample (e.g., blood) obtained from the subject with a glycocalyx-mimetic adsorption media. The adsorption media includes glycosaminoglycan structures and, optionally, proteoglycan core proteins, which are conducive to enhancing and/or restoring the impaired glycocalyx barrier function in a sample. The contacted sample is subsequently separated from the adsorption media, producing a treated sample that can be infused into the subject. Methods and devices for treating a patient suffering from a disease associated with glycocalyx barrier dysfunction are also provided herein.

Methods (300), devices, and systems of processing blood are described. The method (300) comprises the steps of: obtaining (312) blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collecting (314) bulk mononuclear blood cells from the blood by leukapheresis implemented using the blood processing device in the closed loop; and enriching (316) concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.

Bioartificial ultrafiltration devices comprising a scaffold comprising a population of cells enclosed in a matrix and disposed adjacent a plurality of channels are provided. The population of cells provides molecules such as therapeutic molecules to a subject in need thereof and is supported by the nutrients filtered in an ultrafiltrate from the blood of the subject. The plurality of channels in the scaffold facilitate the transportation of the ultrafiltrate and exchange of molecules between the ultrafiltrate and the population of cells.

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.

Embodiments are described for treating a fluid, e.g., a biological fluid. The embodiments may include systems, apparatuses, and methods. Embodiments may provide for a flow cell, with a plurality of manipulation elements, through which a fluid is flowed. The fluid may be treated (e.g., exposed to energy) as it moves through the flow cell. In embodiments, the flow cell may be used to inactivate pathogens in the fluid.

Methods (300), devices, and systems of processing blood are described. The method (300) comprises the steps of: obtaining (312) blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collecting (314) bulk mononuclear blood cells from the blood by leukapheresis implemented using the blood processing device in the closed loop; and enriching (316) concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.